|Mr. Kare Schultz||Pres, CEO & Director||5.6M||N/A||1961|
|Mr. Eliyahu Sharon Kalif||Exec. VP & CFO||655.76k||N/A||1973|
|Dr. Hafrun Fridriksdottir||Exec. VP of Global R&D||2.48M||N/A||1962|
|Mr. Brendan O'Grady||Exec. VP of North America Commercial||1.56M||N/A||1967|
|Mr. Gianfranco Nazzi||Exec. VP of International Markets Commercial||2.15M||N/A||1969|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Teva Pharmaceutical Industries Limited’s ISS governance QualityScore as of 9 December 2019 is 5. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 7; Compensation: 8.